Dow Jones

40,954.48

1.85%

Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) News

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALTH

<< Previous 4 5 6 7 8 9 10 11 12 13 14 15 Next >>

Date	Time	Source	Headline	Symbol	Company
03/03/2005	11:00	PR Newswire (US)	Allos Therapeutics Announces $50 Million Financing	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/01/2005	13:00	PR Newswire (US)	Allos Therapeutics Initiates Phase 1 PDX Study in Patients With Non-Small Cell Lung Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/01/2005	13:01	PR Newswire (US)	Allos Therapeutics Announces Expansion of ENRICH Trial Into Europe	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/12/2004	13:00	PR Newswire (US)	Allos Therapeutics Licenses New Cancer Compound	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/12/2004	16:38	PR Newswire (US)	Allos Therapeutics Investigator Presents Updated Survival Results From Phase III REACH Study at San Antonio Breast Cancer Sympos	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2004	11:00	PR Newswire (US)	Allos Therapeutics to Present at Credit Suisse First Boston's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/11/2004	13:01	PR Newswire (US)	Allos Therapeutics Announces Presentation on EFAPROXYN(TM) at Chemotherapy Foundation Symposium XXII	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/11/2004	21:30	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2004	21:30	PR Newswire (US)	Allos Therapeutics To Hold Third Quarter 2004 Financial Results Conference Call and Webcast on Tuesday, November 9	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
31/10/2004	14:00	PR Newswire (US)	Updated Results of Allos' Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/10/2004	14:00	PR Newswire (US)	Allos Therapeutics to Present at Rodman & Renshaw Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/10/2004	14:00	PR Newswire (US)	Allos Therapeutics Appoints Marc Graboyes as Vice President, General Counsel	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/10/2004	22:30	PR Newswire (US)	Response at Three-Months Post WBRT Found to be Statistically Significant Predictor of Survival in Largest Ever Randomized Study	NASDAQ:ALTH
04/10/2004	20:30	PR Newswire (US)	Prognostic Factors Influencing Survival in Patients with Brain Metastases Identified in Largest Ever Randomized Study	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	21:23	PR Newswire (US)	Allos Therapeutics Receives Orphan Drug Designation From U.S. FDA for EFAPROXYN(TM)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	13:45	PR Newswire (US)	Reminder - Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/08/2004	12:00	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2004 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
29/07/2004	14:00	PR Newswire (US)	Allos Therapeutics to Hold Q2 2004 Financial Results Conference Call and Webcast on Tuesday, August 3	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/06/2004	14:01	PR Newswire (US)	Allos Therapeutics Announces New Trade Names for Efaproxiral in the U.S. and Europe	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/06/2004	14:00	PR Newswire (US)	Allos to Present at Needham and Company's Third Annual Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/06/2004	14:01	PR Newswire (US)	Data Presented at ASCO Demonstrate That Red Blood Cell Levels of Allos Therapeutics' RSR13 Correlate With Treatment Effect in Pa	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/06/2004	19:05	PR Newswire (US)	Data From Phase 3 Trial of Allos Therapeutics' RSR13 (efaproxiral) Presented at ASCO	NASDAQ:ALTH
06/06/2004	18:23	PR Newswire (US)	Analysis From Phase 3 Trial Suggests That Some Non-Small Cell Lung Cancer Patients With Brain Metastases May Benefit From Allos	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/06/2004	14:00	PR Newswire (US)	Allos Therapeutics Files Application for European Marketing Approval of RSR13 (efaproxiral)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/06/2004	15:00	PR Newswire (US)	Federman & Sherwood Announces That a Securities Class Action Lawsuit Was Filed Against Allos Therapeutics, Inc.	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
02/06/2004	14:00	PR Newswire (US)	Allos Therapeutics Receives FDA Approvable Letter for RSR13 (efaproxiral)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
28/05/2004	14:00	PR Newswire (US)	Abstracts on Allos Therapeutics' RSR13 to Be Presented at American Society of Clinical Oncology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
25/05/2004	17:23	PR Newswire (US)	Wolf Haldenstein Adler Freeman and Herz LLP Commences Class Action Lawsuit on Behalf of Allos Therapeutics, Inc. Shareholders	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
24/05/2004	22:13	PR Newswire (US)	Geller Rudman Announces Class Action Lawsuit Against Allos Therapeutics, Inc. on Behalf of Investors	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
24/05/2004	21:13	PR Newswire (US)	Shareholder Class Action Filed Against Allos Therapeutics, Inc. by the Law Firm of Schiffrin & Barroway, LLP	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)